All Stories

  1. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

    Article • Journal of Medical Economics, April 2019, Taylor & Francis

    Dr Zhong Yuan, veronica ashton

  2. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients

    Article • Current Medical Research and Opinion, October 2018, Taylor & Francis

    veronica ashton

  3. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

    Article • Journal of Medical Economics, March 2018, Taylor & Francis

    Ms Yongling Xiao, veronica ashton

  4. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies

    Article • Current Medical Research and Opinion, July 2017, Taylor & Francis

    veronica ashton

  5. Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence

    Article • Current Medical Research and Opinion, July 2017, Taylor & Francis

    veronica ashton